Fresenius stock rises to EUR 44.80 after guidance lift

Published on 09/30/2026 at 11:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius stock posted EUR 5.864 billion revenue in Q2 2026, up 6 percent year over year. Core EPS rose 14 percent, while Barclays kept its EUR 57.50 target on September 16, 2026.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius stock (ISIN DE0005785604) was last at EUR 44.80 on Xetra on September 30, 2026 at 11:25 a.m. CEST, up 1.37 percent from the prior session close of EUR 44.20. The latest operating figures show why the share remains tied to the company’s raised 2026 outlook.

Q2 revenue rises 6 percent

According to Fresenius, Q2 2026 revenue reached EUR 5.864 billion before special items, an organic increase of 6 percent from EUR 5.571 billion in Q2 2025. Core EBIT rose 10 percent in constant currency to EUR 719.0 million from EUR 654.0 million.

Core net income increased 14 percent to EUR 470.0 million, compared with EUR 412.0 million in Q2 2025, while core EPS advanced 14 percent to EUR 0.83 from EUR 0.73. The comparison points to earnings growth outpacing revenue growth, a meaningful change in the company’s operating profile.

Barclays sees EUR 57.50

finanzen.net reported on September 16, 2026 that Barclays kept its Overweight rating and EUR 57.50 price target for Fresenius. The target is 28.24 percent above the Xetra price of EUR 44.80, calculated from the same-day quote context.

The company’s latest investor-relations update also identifies Q2 2026 as a quarter of structural improvement and says the full-year 2026 outlook was raised. Helios generated EUR 3.526 billion of Q2 revenue, up 5 percent, while Kabi revenue reached EUR 2.244 billion, up 7 percent.

Fresenius stock stays below yearly high

Fresenius had a market capitalization of EUR 25.2 billion as of September 30, 2026. Its 52-week range was EUR 35.11 to EUR 52.96, leaving the Xetra price EUR 8.16 below the yearly high.

The next scheduled Q3 2026 telephone conference is listed for November 4, 2026. For investors, the central test is whether the Q2 earnings mix and the higher outlook can continue to support margins across Kabi and Helios.

Stock gains 1.37 percent

Fresenius stock was last at EUR 44.80 on Xetra on September 30, 2026 at 11:25 a.m. CEST, up 1.37 percent versus the prior session close of EUR 44.20. The next earnings date listed by Fresenius is November 4, 2026.